title: Non-steroidal anti-inflammatory drug (NSAID) use and breast cancer risk in the Western New York Exposures and Breast Cancer (WEB) Study.
abstract: OBJECTIVE
  Chronic inflammation is suspected to have a role in breast carcinogenesis. Results of studies of non-steroidal anti-inflammatory drugs (NSAIDs) and breast cancer have been inconsistent. Timing of exposure and analysis of individual NSAIDs should be considered.
  
  
  METHODS
  We conducted a population-based case-control study in western New York State between 1996 and 2001. Cases, 35-79 years, had incident, primary, histologically confirmed breast cancer (n = 1,170). Controls (n = 2,115) were randomly selected from NY Department of Motor Vehicles records (<65 years) or Medicare rolls (>or=65 years). Participants were queried on use of aspirin, ibuprofen, and acetaminophen in the year prior and on aspirin during adulthood. Unconditional logistic regression was used to estimate adjusted odds ratios (OR) and 95% confidence intervals (95% CI).
  
  
  RESULTS
  Recent aspirin use was inversely associated with breast cancer risk (adjusted OR 0.80, 95% CI: 0.68-0.94); the strongest reduction in risk was observed among those who took >or=2 pills/day on days that aspirin was taken (OR 0.74, 95% CI: 0.61-0. 90). Adult lifetime use was also associated with breast cancer risk (>10 days/month, adjusted OR 0.68, 95% CI: 0.46-1.00). Use of ibuprofen or acetaminophen was not associated with breast cancer.
  
  
  CONCLUSIONS
  This is the first study to investigate the association of adult lifetime aspirin intake with breast cancer risk. Our findings provide evidence that aspirin use throughout a woman's life may confer some benefit.
authors.affiliation: Department of Social and Preventive Medicine, School of Public Health and Health Professions, University at Buffalo, Buffalo, NY 14214, USA. tbrasky@fhcrc.org
authors.forename: Theodore M
authors.initials: TM
authors.lastname: Brasky
authors.forename: Matthew R
authors.initials: MR
authors.lastname: Bonner
authors.forename: Kirsten B
authors.initials: KB
authors.lastname: Moysich
authors.forename: Christine B
authors.initials: CB
authors.lastname: Ambrosone
authors.forename: Jing
authors.initials: J
authors.lastname: Nie
authors.forename: Meng Hua
authors.initials: MH
authors.lastname: Tao
authors.forename: Stephen B
authors.initials: SB
authors.lastname: Edge
authors.forename: Bhaskar V S
authors.initials: BV
authors.lastname: Kallakury
authors.forename: Catalin
authors.initials: C
authors.lastname: Marian
authors.forename: Maurizio
authors.initials: M
authors.lastname: Trevisan
authors.forename: Peter G
authors.initials: PG
authors.lastname: Shields
authors.forename: Jo L
authors.initials: JL
authors.lastname: Freudenheim
mesh_terms: D000328:Adult; D000368:Aged; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000494:pharmacology*; D001241:Aspirin / Q000494:pharmacology*; D001943:Breast Neoplasms / Q000453:epidemiology*; D016022:Case-Control Studies; D005260:Female; D006801:Humans; D008875:Middle Aged; D009518:New York; D016017:Odds Ratio; D012307:Risk Factors; D011795:Surveys and Questionnaires
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D001241:Aspirin